Close Menu

NEW YORK – Biolidics said today that its ClearCell FX1 System has obtained a Class I registration from the China National Medical Products Administration.

ClearCell FX1 is a liquid biopsy platform that separates and enriches cancer cells from a blood sample for either quantitation or further analyses like molecular and genomic profiling.

With the NMPA approval, Biolidics can now directly market and sell the platform to hospitals, laboratories, research institutions, and other medical institutions for use in in vitro diagnostic testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.